Fierce Biotech

ESMO: BMS’ Massacesi hails ‘very promising’ data for BioNTech-partnered PD-L1xVEGF-A drug

Bristol Myers Squibb Chief Medical Officer Cristian Massacesi, M.D., has told Fierce that the latest data for its ...
Fierce Biotech

ESMO: AstraZeneca exec insists phase 3 ADC data ‘robust’ enough for regulators despite PFS miss

AstraZeneca executives were adamant that detailed data from a phase 3 study of the pharma’s next-generation antibody-drug ...
Fierce Biotech

ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals

Roche has shed more light on its investigational KRAS G12C inhibitor's phase 3 victory over Amgen’s Lumakras and Bristol Myers Squibb’s Krazati. | Roche has shed more light on its investigational KRAS ...